ICICI Securities: Nestle India’s Infant Food Business Will Likely Face Growth Headwinds In CY 2021
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Securities Report
Nestle India Ltd.’s infant nutrition business (approximately 30% of revenues and approximately 40% of profits) will likely face growth headwinds in CY2021 due to consumers (now) delaying plans of having babies due to fear of visiting hospitals.
Given the premium pricing of infant nutrition products, the consuming households are mostly the upper-middle class/middle class, in our view.
We have drawn conclusions from:
- our primary research with pharmaceutical companies and
- secondary sales data (market research) from All Indian Origin Chemists and Distributors-Advanced Working, Action and Correction System (AIOCD-AWACS)
Though we are believers in Nestle’s long-term story, our current neutral stance is intact (given that only a part of its portfolio (Maggi and (somewhat) Coffee) would benefit from increased in-home consumption).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the brokerage and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.